Investors in MoonLake Immunotherapeutics Encouraged to Join Class Action Lawsuit

Class Action Lawsuit for MoonLake Immunotherapeutics Shareholders

Investors in MoonLake Immunotherapeutics, widely referred to as MoonLake, are being urged to participate in a class action lawsuit aimed at recovering financial losses purportedly incurred due to alleged securities fraud. The firm Levi & Korsinsky, LLP has publicly notified shareholders about this imminent legal action concerning MoonLake (NASDAQ: MLTX).

Overview of the Class Action

The class action lawsuit is designed for shareholders who experienced adverse impacts due to alleged fraudulent activities associated with the company. The filing states that affected investors are those who held shares in MoonLake between March 10, 2024, and September 29, 2025.

Why Are Shareholders Being Informed?

As part of the notice, those who suffered losses during this specific timeframe are encouraged to take action before the deadline of December 15, 2025, to have a chance of being appointed as lead plaintiffs in the case. Importantly, shareholders do not need to serve as lead plaintiffs to qualify for potential compensation from any recovery.

Case Details

The complaint accuses the defendants of making false statements or withholding critical information regarding MoonLake's drug candidate, known as SLK. Key allegations include:
1. SLK and BIMZELX, another drug, were said to target the same inflammatory cytokines IL-17A and IL-17F, leading to misleading comparisons.
2. Claims were made that SLK's distinct Nanobody structure would offer superior clinical benefits over the traditional monoclonal antibodies used in BIMZELX, a statement claimed to lack a reasonable basis.
3. Assertions about SLK's increased tissue penetration not translating to clinical efficacy were also cited as misleading.

The essence of these allegations lies in the fact that the optimistic portrayals of SLK's potential advantages over existing treatments may have inflated investor confidence, which, upon the revelation of the situation, could lead to significant financial repercussions.

The Path Moving Forward

For anyone who believes they qualify for this class action, it is crucial to act swiftly. By visiting the Levi & Korsinsky website, investors can find more information and fill out required forms to participate in the suit. Contact information for the legal team is also provided, encouraging investors to reach out directly for inquiries regarding their status or potential damages.

No Financial Burden for Class Members

Should shareholders qualify as class members, they can expect involvement in the lawsuit without incurring out-of-pocket expenses. Levi & Korsinsky has stated that there is no obligation or cost to participate.

Why Join Levi & Korsinsky?

Levi & Korsinsky has established a robust reputation over the past two decades for representing aggrieved shareholders, recovering hundreds of millions in damages through other similar lawsuits. The firm is known for its expertise in complex securities litigation, which is critical in navigating the intricacies of these cases. Furthermore, Levi & Korsinsky has consistently ranked among the leading securities litigation firms within the United States.

Conclusion

As the legal landscape for MoonLake Immunotherapeutics investors evolves, those who believe they were misled should consider joining the class action. With the impending deadline approaching, timely action can help investors recover potential losses and ensure accountability for the alleged corporate misconduct.

For additional information or to reach out for legal assistance, investors may contact Levi & Korsinsky directly as outlined in the notification. They stand ready to support affected shareholders in their pursuit of justice and recompense.